arrow
J

Jonas Bergh

karolinska institutet
H指数:103
被引数:7.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glucocorticoid prophylaxis influences the systemic immune macroenvironment in patients with early stage, treatment naïve, HER2+ breast cancer

糖皮质激素预防对早期、治疗初治、HER2阳性乳腺癌患者的全身免疫宏观环境的影响

2026-08-250
OA
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

新辅助palbociclib联合内分泌治疗与化疗在ER+/HER2-乳腺癌中的比较:一项随机II期试验

2026-04-080
OAAI
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study

乳腺癌患者接受阿贝西利或瑞博西利辅助治疗的患病率与预后:一项全国性基于人群的研究

2025-09-290
OAAI
Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study

乳腺癌患者新辅助治疗期间肿瘤Ki-67动态变化的预后意义:一项基于人群的队列研究

2025-09-020
PREAI
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer
2024-12-270
PRE
Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images

揭示模型不可知的多尺度分析的力量,以增强乳腺癌组织病理学图像中的人工智能模型

2024-09-010
OA
Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study

使用[89Zr]Zr-阿替利珠单抗正电子发射断层扫描/计算机断层扫描(PET/CT)对转移性三阴性乳腺癌(mTNBC)患者程序性死亡配体1(PD-L1)表达进行分子成像:MIMIR研究

2024-09-010
PRE
A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)

一项曲妥珠单抗德鲁替康和生物驱动的 HER2 阳性乳腺癌新辅助治疗方案选择的随机试验(ARIADNE)

2024-09-010
PRE
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

6th和7th晚期乳腺癌管理国际共识指南 (ABC指南6和7)

BREAST
IF7.9
2024-08-0122
OAAI
Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally
2024-07-010
PRE
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
2024-06-243
OAAI
Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials
2024-05-020
PRE